Iovance Biotherapeutics, Inc. Common Stock
Here’s whether Iovance Biotherapeutics, Inc. Common Stock (IOVA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.62% over 10 days); RSI 58 — healthy momentum range; strong 1-year return of +25.7%; 3-month momentum positive (+63.6%). Currently 31.4% off its 52-week high. Score: +7/7.
IOVA is in a confirmed uptrend, trading above both its 50-day ($3.59) and 200-day ($2.68) moving averages. An RSI of 57.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +25.7% compares to +35.1% for SPY (trailed the market by 9.4%). The current 31.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.